Abstract
Patients undergoing standard highly-active antiretroviral therapy for the treatment of human immunodeficiency virus may suffer from severe facial lipotrophy, also known as facial wasting. Facial wasting can impose a devastating psychosocial burden to the affected patients. Injectable filler materials are currently used worldwide for soft-tissue augmentation in various parts of the body. Injectable filler materials can be absorbable, semipermanent, or permanent. Permanent injectable filler materials have been used to augment facial soft-tissue defects, to treat rhytids, or to treat patients affected by facial lipoatrophy secondary to human immunodeficiency virus–associated antiretroviral therapy.
Get full access to this article
View all access options for this article.
